D201 dupilumab efficacy in patients with uncontrolled, moderate-to-severe asthma and serologic evidence of allergic bronchopulmonary aspergillosis

Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for IL-4/IL-13, key drivers of type 2 inflammation in multiple diseases. In the phase 3 LIBERTY ASTHMA QUEST study (NCT02414854), add-on dupilumab 200mg/300mg every 2 weeks vs placebo reduced severe exacerbations and improved pre-bronchodilator FEV1 in patients with uncontrolled, moderate-to-severe asthma. Treatment effects were greater in patients with elevated baseline type 2 biomarkers. Allergic bronchopulmonary aspergillosis (ABPA) is characterized by Aspergillus fumigatus (Af) hypersensitivity and robust type 2 inflammatory responses.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Source Type: research